The Latest

COUR Pharmaceuticals Enters Collaboration and Licensing Agreement with Genentech to Develop and Commercialize Tolerogenic Therapy for the Treatment of an Autoimmune Disease

Skip to primary navigation
Skip to main content
Skip to footer

COUR Pharmaceuticals

Our Company
Our Technology
- Pipeline
Our Clinical Trials
- CNP-106 Myasthenia Gravis
Publications & Media
- Press Releases
- Publications
Careers

Connect With Us

First Name

Last Name

Email

Phone Number
Please leave this field empty.

Subject

Message

Footer

Our Company
Our Technology
Our Partners
Press
Careers

©

2024

COUR Pharmaceuticals.
All Rights Reserved.

Privacy Policy • Terms of Use